We are live on
!
Find out more
DY
Dowling & Yahnke Portfolio holdings
AUM
$2.15B
Turnover
6.98%
1-Year Est. Return
10.82%
This Fund
S&P 500
This Quarter
Est. Return
-4.54%
1 Year Est. Return
-10.82%
3 Year Est. Return
+34.82%
5 Year Est. Return
+71.23%
10 Year Est. Return
–
AUM
$2.15B
AUM Growth
+$21.9M
(+1%)
Cap. Flow
+$140M
Cap. Flow
% of AUM
6.52%
Top 10 Holdings %
Top 10 Hldgs %
29.72%
Holding
387
New
13
Increased
178
Reduced
139
Closed
14
Avg Time Held
5.5
years
Top 10 Avg Time Held
1.8
years
Top 20 Avg Time Held
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dimensional International Core Equity Market ETF
DFAI
|
+$30.3M |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$24.2M |
| 3 |
Vanguard Total International Stock ETF
VXUS
|
+$23.3M |
| 4 |
Vanguard Short-Term Corporate Bond ETF
VCSH
|
+$13.8M |
| 5 |
Vanguard Short-Term Inflation-Protected Securities Index Fund
VTIP
|
+$10.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Tax-Exempt Bond Index Fund
VTEB
|
+$16.8M |
| 2 |
Vanguard FTSE All-World ex-US ETF
VEU
|
+$4.06M |
| 3 |
Northrop Grumman
NOC
|
+$2.81M |
| 4 |
Leidos
LDOS
|
+$2.15M |
| 5 |
Saic
SAIC
|
+$1.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 51.91% |
| 2 | Technology | 10.65% |
| 3 | Healthcare | 9.36% |
| 4 | Financials | 6.57% |
| 5 | Consumer Staples | 5.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
351
Broadstone Net Lease
BNL
$3.48B
| $205K | 0.01% |
13,216
| – | – |
2021 Q2
5 quarters
|
|
352
Dell
DELL
$301B
| $202K | 0.01% |
5,900
-130
| -2% | -$5.47K |
2019 Q1
14 quarters
|
|
353
Kinder Morgan
KMI
$73.1B
| $195K | 0.01% |
11,708
-113
| -1% | -$2.01K |
2017 Q4
19 quarters
|
|
354
Gossamer Bio
GOSS
$54.4M
| $181K | 0.01% |
189
| – | – |
2022 Q1
2 quarters
|
|
|
RNAM
355
DELISTED
Avidity Biosciences
RNAM
| $175K | 0.01% |
10,691
-590
| -5% | -$11.3K |
2021 Q1
6 quarters
|
|
356
Lumen Technologies, Inc. Common Stock
LUMN
$5.02B
| $172K | 0.01% |
23,678
-2,672
| -10% | -$27.2K |
2021 Q2
5 quarters
|
|
357
Guggenheim Strategic Opportunities Fund
GOF
$1.92B
| $164K | 0.01% |
10,705
+340
| +3% | +$5.66K |
2022 Q1
2 quarters
|
|
358
BlackRock Health Sciences Trust II
BMEZ
$1.03B
| $149K | 0.01% |
+10,000
| New | +$165K |
2022 Q3
0 quarters
|
|
359
iShares US Oil Equipment & Services ETF
IEZ
$334M
| $144K | 0.01% |
10,000
| – | – |
2020 Q4
7 quarters
|
|
360
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $134K | 0.01% |
7,523
| – | – |
2019 Q3
12 quarters
|
|
361
DELISTED
Chimerix, Inc.
CMRX
| $124K | 0.01% |
64,055
| – | – |
2019 Q3
12 quarters
|
|
362
Ouster
OUST
$2.26B
| $106K | ﹤0.01% |
+10,955
| New | +$169K |
2022 Q3
0 quarters
|
|
363
Viatris
VTRS
$20.9B
| $102K | ﹤0.01% |
12,023
-865
| -7% | -$8.51K |
2020 Q4
7 quarters
|
|
364
Geron
GERN
$790M
| $91K | ﹤0.01% |
39,047
| – | – |
2020 Q4
7 quarters
|
|
|
TCON
365
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $79K | ﹤0.01% |
2,373
| – | – |
2020 Q1
10 quarters
|
|
|
SNCE
366
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $68K | ﹤0.01% |
2,113
-1,000
| -32% | -$37.1K |
2022 Q2
1 quarter
|
|
367
Grifois
GRFS
$5.13B
| $67K | ﹤0.01% |
10,955
| – | – |
2013 Q2
37 quarters
|
|
368
SiriusXM
SIRI
$9.15B
| $60K | ﹤0.01% |
1,053
+23
| +2% | +$1.45K |
2021 Q3
4 quarters
|
|
369
Strata Critical Medical Inc
SRTA
$384M
| $40K | ﹤0.01% |
10,000
| – | – |
2021 Q2
5 quarters
|
|
370
SelectQuote
SLQT
$60.9M
| $40K | ﹤0.01% |
55,000
| – | – |
2022 Q1
2 quarters
|
|
371
Lineage Cell Therapeutics
LCTX
$250M
| $36K | ﹤0.01% |
32,263
| – | – |
2022 Q2
1 quarter
|
|
372
Fortress Biotech
FBIO
$63.7M
| $17K | ﹤0.01% |
1,333
| – | – |
2019 Q1
14 quarters
|
|
|
STAB
373
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
| $4K | ﹤0.01% |
28,875
| – | – |
2021 Q3
4 quarters
|
|
374
American Water Works
AWK
$26.4B
| – | – |
-1,655
| Closed | -$246K | – |
|
375
Church & Dwight Co
CHD
$24.5B
| – | – |
-2,499
| Closed | -$232K | – |
|
Similar funds
AC
APA
IC
SCA
ACM
W
Dowling & Yahnke's Q3 2022 Portfolio in Review
As of Q3 2022, Dowling & Yahnke held 387 positions worth $2.15B, up 1% from $2.13B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Dowling & Yahnke deployed $140M of net new capital in Q3 2022, opening 13 new positions and adding to 178 existing holdings. Its largest new stake was U.S. High Relative Profitability Portfolio ETF Class Shares: 161,010 shares worth $3.44M.
By sector, the portfolio is most concentrated in Miscellaneous at 52% of assets, up from 49% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Vanguard Tax-Exempt Bond Index Fund, an estimated $16.8M trimmed.
- Dowling & Yahnke's largest Q3 2022 buy was U.S. High Relative Profitability Portfolio ETF Class Shares: 161,010 shares worth $3.44M.
- Dowling & Yahnke added most to Dimensional International Core Equity Market ETF in Q3 2022, an estimated $30.3M increase.
- Dowling & Yahnke's biggest Q3 2022 reduction was Vanguard Tax-Exempt Bond Index Fund, cutting an estimated $16.8M.
- Dowling & Yahnke fully exited Saic in Q3 2022, selling an estimated $1.57M.
- Dowling & Yahnke's ten largest holdings make up 30% of its $2.15B portfolio in Q3 2022.
- Dowling & Yahnke opened 13 new positions and closed 14 in Q3 2022.
- Dowling & Yahnke's portfolio value rose 1% quarter-over-quarter to $2.15B.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.